Preemptive Pharmacogenetics in Renal Transplantation: A Real-World Assessment of Pharmacogenetic Actionability

Real-world assessment of pharmacogenetic actionability in a preemptive PGx program for renal transplantation (*CYP3A5*-tacrolimus, *CYP2C19*-proton pump inhibitors, *SLCO1B1*-statins)

A retrospective study of 110 renal transplant recipients evaluates the theoretical and effective actionability of a preemptive PGx program. While theoretical actionability reaches 99%, effective post-transplant actionability is 26%, reflecting real clinical constraints (co-prescriptions, interactions, therapeutic priorities). Priority gene-drug pairs identified are CYP3A5-tacrolimus, CYP2C19-proton pump inhibitors, and SLCO1B1-statins.

Synthesis written by Geno'X. For the full original abstract, please refer to the source publication.

The gap between 99% theoretical actionability and 26% effective actionability is precious data for implementation programs. These results underscore the importance of prioritizing gene-drug pairs by contextual clinical relevance rather than by volume. A useful model for teams wishing to develop a preemptive PGx program in a transplantation unit.